독일의 의약품 콜드체인 물류 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the germany pharmaceutical cold chain logistics market size is expected to grow from USD 0.91 billion in 2025 to USD 0.96 billion in 2026 and is forecast to reach USD 1.33 billion by 2031 at 6.88% CAGR over 2026-2031.

This report is Segmented by Service Type (Transportation [Road, Air, Sea, Rail], Warehousing & Distribution, and Value-Added Services), by Temperature Type (Chilled, Frozen, and Ambient), by Product (Generic Drugs, and Branded Drugs), and by Application (Biopharma, Chemical Pharma, and Specialized Pharma). The Market Forecasts are Provided in Terms of Value (USD Billion).

Germany Pharmaceutical Cold Chain Logistics Market Trends and Insights

Expansion of Biopharma Manufacturing in Bavaria and Baden-Wurttemberg

Eli Lilly's EUR 2.3 billion (USD 2.5 billion) plant in Aley, operational by 2027, underscores how western and southern corridors are scaling biologics and incretin therapy output that moves under 2-8°C protocols from fill-finish to dispensing. Roche's continued capital commitment in Germany adds further momentum across Baden-Wurttemberg and adjacent states, reinforcing a dense cluster of global players that value regulatory speed and specialized labor. This clustering reduces inter-facility transfer time, strengthens reverse-logistics loops, and creates multi-depot density that GDP-certified carriers convert into efficient milk runs and full-truckload lanes. Proximity to Frankfurt and Stuttgart intermodal gateways improves route control and reduces ambient risk during transshipment for high-value biologics. The result is a more consolidated outbound flow from the south and west that improves asset utilization for carriers and stabilizes service-level performance in the Germany pharmaceutical cold chain logistics market.

Germany as a Central European Pharmaceutical Distribution Hub

DHL's expanded Life Sciences & Healthcare campus in Florstadt adds 100,000 square meters of GDP-compliant space and more than 140,000 pallet positions across multi-temperature zones, which strengthens Germany's position as a central European pharma hub served by Frankfurt Airport. The site supports APIs, hazardous materials, and raw materials within GMP conditions, aligning with strict European and international standards for life sciences customers across the region. Germany's multimodal backbone, including the Rhine-Main-Danube corridor and high-speed rail, links North Sea gateways to Alpine manufacturing and helps consolidate pharmaceutical flows. For specialized therapies that need sub-24-hour delivery and chain-of-identity controls, Germany's hub-and-spoke architecture enables overnight staging and same-morning hospital or home-care dispatch. This integrated network effect is a structural advantage that sustains the Germany pharmaceutical cold chain logistics market over the long term.

High Energy Costs Impacting Refrigeration Economics

Cold storage and active refrigerated transport depend on energy-intensive systems, so price volatility tightens margins and limits the ability to add surge capacity quickly. Producer price movements underscore cost sensitivity within German manufacturing, which influences the cost base for temperature-controlled operations and related services. Sites with high refrigeration density, such as port-adjacent warehouses, face peak-load challenges during seasonal extremes that raise contingency costs. Carriers respond with route and load consolidation, but residual exposure persists for shipments that require dedicated capacity or short-notice dispatch. These pressures can delay upgrades to -20°C and -70°C infrastructure, which in turn affects service breadth in the Germany pharmaceutical cold chain logistics market.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Direct-to-Patient Home Delivery Programs
2. Increasing Clinical Trial Activity for Cell and Gene Therapies
3. Driver Shortage for GDP-Certified Cold Chain Transportation

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Transportation held 41.78% of segment value in 2025, which anchors the current mix even as value-added services post the fastest 6.87% CAGR through 2031. Road distribution remains the backbone for domestic flows across production nodes in Bavaria, North Rhine-Westphalia, and Hesse, while air freight bridges time-critical biologics and clinical materials through Frankfurt. Ocean and rail have a smaller role for domestic movements, yet they contribute to import-export corridors and upstream API consolidation. Warehousing and distribution absorb a growing share due to multi-zone GDP facilities, validated cold rooms, and continuous monitoring that many pharma clients outsource. DHL's Florstadt campus illustrates how integrated warehousing with 2-8°C, -20°C, and down to -70°C zones supports a wider service envelope for biopharma and clinical research customers. GEODIS's GDP certification for ocean freight in Hamburg strengthens multimodal continuity from vessel to GDP warehouse, which reduces handoff risk for inbound or transshipment flows. The Germany pharmaceutical cold chain logistics market benefits when carriers can wrap transport, storage, and compliance-heavy add-ons into single contracts that reduce audit overhead for shippers.

Transportation will remain central as value-added services scale because manufacturers want fewer handoffs with richer compliance coverage. This is most visible in temperature excursion management, controlled returns, and clinical sample handling that sit adjacent to core transport. Eurotranspharma's bi-temperature distribution shows how fleet-level design can support mixed consignments in one route plan, which reduces the need for passive packaging on every parcel. As more contracts expand to end-to-end scope, carriers that integrate storage, labeling, relabeling, and batch-certified kitting gain traction in the Germany pharmaceutical cold chain logistics industry. The shift favors operators with audited IT systems and telemetry that demonstrate GDP adherence in real time. These attributes underpin price resilience against low-cost bids in the Germany pharmaceutical cold chain logistics market.

List of Companies Covered in this Report:

1. Trans-o-flex (ThermoMed)
2. DHL
3. Transmed Transport GmbH
4. GDP Network Solutions GmbH
5. Kuehne + Nagel
6. Biotech and Pharma Logistics
7. Rhenus Logistics
8. Ceva Logistics
9. DB Schenker
10. Pfenning Logistics
11. FedEx Logistics
12. MSK Pharma Logistics
13. Eurotranspharma
14. NextPharma Logistics GmbH
15. B+S GmbH Logistik und Dienstleistungen
16. SK Pharma Logistics GmbH
17. Logistics4Pharma
18. BPL - Biotech & Pharma Logistics GmbH
19. FIEGE Logistics
20. Logwin AG

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of Biopharma Manufacturing in Bavaria and Baden-Wurttemberg
  • 4.2.2 Germany as Central European Pharmaceutical Distribution Hub
  • 4.2.3 Growing Direct-to-Patient Home Delivery Programs
  • 4.2.4 Increasing Clinical Trial Activity for Cell and Gene Therapies
  • 4.2.5 Premium Pricing Tolerance for Temperature-Assured Logistics
  • 4.2.6 Rising mRNA Vaccine Production Following Pandemic Infrastructure
• 4.3 Market Restraints
  • 4.3.1 High Energy Costs Impacting Refrigeration Economics
  • 4.3.2 Driver Shortage for GDP-Certified Cold Chain Transportation
  • 4.3.3 Infrastructure Limitations in Former East German Regions
  • 4.3.4 Intense Price Competition from Eastern European Logistics Providers
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry
• 4.8 Impact of Geo-Politics Events on the Market

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Service Type
  • 5.1.1 Transportation
    • 5.1.1.1 Road
    • 5.1.1.2 Air
    • 5.1.1.3 Sea
    • 5.1.1.4 Rail
  • 5.1.2 Warehousing & Distribution
  • 5.1.3 Value-Added Services
• 5.2 By Temperature Type
  • 5.2.1 Chilled
  • 5.2.2 Frozen
  • 5.2.3 Ambient
• 5.3 By Product
  • 5.3.1 Generic Drugs
  • 5.3.2 Branded Drugs
• 5.4 By Application
  • 5.4.1 Biopharma
  • 5.4.2 Chemical Pharma
  • 5.4.3 Specialized Pharma

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Trans-o-flex (ThermoMed)
  • 6.4.2 DHL
  • 6.4.3 Transmed Transport GmbH
  • 6.4.4 GDP Network Solutions GmbH
  • 6.4.5 Kuehne + Nagel
  • 6.4.6 Biotech and Pharma Logistics
  • 6.4.7 Rhenus Logistics
  • 6.4.8 Ceva Logistics
  • 6.4.9 DB Schenker
  • 6.4.10 Pfenning Logistics
  • 6.4.11 FedEx Logistics
  • 6.4.12 MSK Pharma Logistics
  • 6.4.13 Eurotranspharma
  • 6.4.14 NextPharma Logistics GmbH
  • 6.4.15 B+S GmbH Logistik und Dienstleistungen
  • 6.4.16 SK Pharma Logistics GmbH
  • 6.4.17 Logistics4Pharma
  • 6.4.18 BPL - Biotech & Pharma Logistics GmbH
  • 6.4.19 FIEGE Logistics
  • 6.4.20 Logwin AG

7 FUTURE OF THE MARKET

8 APPENDIX

• 8.1 Macroeconomic Indicators (GDP Distribution, by Activity)
• 8.2 Economic Statistics - Transport and Storage Sector Contribution to Economy
• 8.3 External Trade Statistics - Exports and Imports by Product and by Country of Destination/Origin